Milk thistle: what it is, how it works, and what research shows

What milk thistle is

Milk thistle (Silybum marianum) is a tall, spiny plant with purple flower heads and white-veined leaves. It belongs to the daisy family, the same botanical family as ragweed, artichokes and daisies. The part used in supplements is the fruit, usually called the seed.

The seeds contain silymarin, a mixture of compounds called flavonolignans. Silibinin (also written silybin) is the main and most-studied component, with smaller amounts of silychristin and silydianin. A 2018 review describes the complex in just those terms and notes that the clinical case for liver disease still needs stronger trials.

You will find it as capsules, tablets, tinctures and tea. It is marketed mostly for liver support, and to a lesser degree for digestion. That is a description of why people buy it, not a finding. The rest of this guide covers what has actually been measured; our milk thistle hub collects deeper pieces on individual questions.

How it works in the body

The usual shorthand is that silymarin is an antioxidant and anti-inflammatory compound. Some trials have measured markers of inflammation and oxidative stress, and a small kidney trial reported lower levels with silymarin. But the more practical story is about absorption, because getting silymarin into the bloodstream is the hard part.

A 2021 systematic review found that silymarin's active compounds are poorly absorbed when swallowed. The body processes and excretes them quickly, so little reaches circulation. That means the number on the label and the amount your tissues see can be far apart.

Manufacturers have tried to close the gap. A 2005 review found that binding silibinin to phosphatidylcholine, a so-called phytosome complex, improves absorption compared with plain silymarin extract. Separately, a 2019 study in rats found that piperine, the active compound in black pepper, raised silibinin availability by 146–181% by blocking transporters that pump it back out of cells. That is an animal and cell-line result. It has not been shown in people.

Poor absorption may be one reason trial results are hard to compare across products and doses, though the sources here do not prove that. It does explain why standardization and formulation matter more than they do for many supplements.

What the liver evidence shows

Liver health is the traditional use and the best-studied one. The results depend heavily on which liver condition is being studied.

One more data point: a 3-month, placebo-controlled trial of a six-ingredient mixture that included silymarin and curcumin, in 113 people with a diagnosed liver condition, found no significant difference from placebo. A 4-week pilot in 15 people reported improvements with silymarin and curcumin, but it was small and its abstract describes no placebo group.

The fair summary is that milk thistle may have a modest role in fatty liver disease, with confirmation pending, and little to show in viral hepatitis or alcohol-related cirrhosis. It is not a replacement for medical care of any liver condition.

Cholesterol, kidneys and other measured effects

A 2024 pooled analysis of 33 trials (1,943 people) found that silymarin lowered total cholesterol, triglycerides and LDL compared with control. HDL, body weight and BMI did not change significantly. The authors say larger, longer trials are needed to confirm it.

Kidney results are mixed. A small trial in people with diabetic kidney disease found that 420 mg/day for 3 months reduced a urine-protein marker more than placebo. A larger trial found no significant difference in kidney function decline, dialysis need or death, although hospitalizations were lower with silymarin.

Some smaller studies have looked at silymarin alongside medical treatment:

• Chemotherapy support: in 30 breast cancer patients, 420 mg/day reduced liver damage severity on ultrasound after a month, though blood-based liver tests did not differ. In 70 colorectal cancer patients, silymarin was linked to less diarrhea and nausea, with no difference in liver toxicity. These are pilot-scale trials, not evidence that milk thistle treats cancer, and anyone in treatment should clear it with their oncology team.
• Heart surgery: a 2024 controlled study of 160 bypass patients found fewer cases of postoperative atrial fibrillation after 400 mg of silymarin beforehand. The study does not state that it was randomized or blinded.
• Weight and blood sugar: a 52-week trial of a berberine-silymarin combination reduced abdominal fat and metabolic markers in obese adults with type 2 diabetes. Berberine has its own metabolic effects, so the result cannot be credited to milk thistle.

Where the evidence is thin or missing

Many claims attached to milk thistle rest on animal studies, lab dishes or combination products. They are worth knowing about mainly so you can discount them.

• Breast milk supply: an NIH monograph reports no valid clinical trial support for milk thistle increasing milk supply.
• Menopause: the available work is in rats and isolated animal tissue, including cardiovascular markers, blood vessel relaxation and bone. None of it tests a menopause symptom in a person.
• Mood and behavior: in a placebo-controlled trial of 43 adults, 300–600 mg/day of silymarin did no better than placebo on gambling, depression or anxiety scores over 8 weeks. A systematic review of stress-related effects describes mostly animal and lab measures, and its authors call for more clinical studies.
• Infections: silymarin showed some antibacterial and antifungal activity in lab dishes, at concentrations well above what a swallowed dose is known to reach in blood. Those are test-tube results, not treatments.
• Skin: small studies of topical products exist for acne, eczema and rosacea, but many lacked a placebo group or tested a blend of ingredients. One acne split-face trial saw improvement on both the silymarin and the salicylic acid side. The eczema evidence in mice is animal only.
• Iron overload: in transfusion-dependent thalassemia, adding silymarin to chelation drugs lowered blood ferritin, but a smaller analysis found no significant reduction in liver iron itself.
• Inflammatory bowel disease: a 2015 review lists silymarin among herbs studied, without reporting a specific trial result or ranking it among the best-supported options.

Safety, allergy and drug interactions

Silymarin looks well tolerated. A 2019 safety review found it generally well tolerated in humans, even at high doses for 24 weeks, with gastrointestinal upset the main limiting side effect. The NIH monograph adds occasional stomach or skin reactions.

The allergy point is easy to miss. Because milk thistle belongs to the daisy family, the monograph flags rare but real cross-reactivity in people allergic to ragweed-family plants.

Drug interactions are less clear-cut. In a 2009 trial, 420 mg/day of silymarin for 14 days changed blood levels of the blood pressure drug losartan in healthy volunteers, but the effect depended on each person's CYP2C9 genotype. In a 2014 study, a standardized extract taken three times daily for 14 days had no significant effect on four major drug-metabolizing liver enzymes. Those findings do not contradict each other so much as show that the answer varies by drug and by person. If you take prescription medication, tell your pharmacist.

Who it's for, and how to choose a product

Milk thistle is best viewed as an option to discuss with a clinician for adults with fatty liver or elevated lipids, where pooled trials show a signal, rather than a general wellness supplement. People who are healthy and simply want a liver cleanse have no trial evidence addressed to them. People with ragweed-family allergies, those on prescription drugs or chemotherapy, and anyone pregnant or breastfeeding should ask first.

If you decide to try it, three label details matter. First, look for an extract standardized to a stated percentage of silymarin. A line reading only "milk thistle extract 1,000 mg" does not tell you how much silymarin you are getting. Second, capsules and tablets of standardized extract are the form used in essentially all human research. Tea is less predictable, since silymarin's components dissolve poorly in water. Third, phytosome products bind silibinin to phosphatidylcholine to improve absorption, which may justify the higher price.

Trial doses ranged from 300 to 600 mg/day of silymarin in most studies, with one hepatitis C trial going to 2,100 mg/day. For how those numbers translate to products, see how much milk thistle to take and how to choose a milk thistle supplement.